Stem Cells & Tissue Engineering
50.7K views | +0 today
Stem Cells & Tissue Engineering
Stem Cells & Tissue Engineering  news and updates
Your new post is loading...
Your new post is loading...
Scooped by Jacob Blumenthal
Scoop.it!

iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF

Jacob Blumenthal's insight:

Researchers found that leukemia inhibitory factor (LIF) secretion by induced pluripotent stem cells (iPSC)-derived neural precursor cells (NPCs) has a neuprotective effect against demyelination.

These NPCs were derived from mouse iPSC and  intrathecally  transplanted into an animal model of multiple sclerosis. Upon transplantation, the cells induced a neurprotective effect not by cell replacement  but through the secretion of LIF  that was shown promotes survival, differentiation and the remyelination capacity of both endogenous oligodendrocyte precursors and mature oligodendrocytes.

http://www.nature.com/ncomms/2013/131022/ncomms3597/full/ncomms3597.html

 

 

more...
No comment yet.
Scooped by Jacob Blumenthal
Scoop.it!

ACT patent filing for MSCs: of Dancing Mice & Multiple Sclerosis

ACT patent filing for MSCs: of Dancing Mice & Multiple Sclerosis | Stem Cells & Tissue Engineering | Scoop.it
Is Advanced Cell Technology (ACT) on the road to cure Multiple Sclerosis (MS) using stem cells? Some folks seem to think it's quite possible, but I remain skeptical. Still there have been some inte...
more...
No comment yet.
Scooped by Jacob Blumenthal
Scoop.it!

FDA Approves Stem Cell Clinical Trial For Multiple Sclerosis

NEW YORK, Aug. 14, 2013 /PRNewswire/ --   The Tisch MS Research Center of New York announced today that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to commence a Phase 1 trial using autologous neural stem cells in the treatment of multiple sclerosis (MS).  MS is a chronic human autoimmune disease of the central nervous system that leads to myelin damage and neurodegeneration and affects approximately 2.1 million people worldwide.
Jacob Blumenthal's insight:

In the approved clinical trial, mesenchymal stem cell-derived neural progenitor cells (MSC-NPs) will be isolated from the patient's bone marrow, expanded and tested prior to injection. Participants will receive three rounds of injections at three month intervals. Safety and efficacy parameters will be evaluated in all participants through regular follow-up visits.The approval of the trial will allow researchers, for the first time to test this treatment strategy in real human patients. Hopefully, this phase I trial will lead to further trials of other stem cells-based potential therapies.

more...
No comment yet.